-
PAD4-IN-2 TFA: Tumor-Targeted PAD4 Inhibition
2026-09-10
PAD4-IN-2 TFA, also called Compound 5i TFA, is a meta-phenylboronic acid-modified PAD4 inhibitor for cancer research. Preclinical evidence links it to reduced histone H3 citrullination, NET formation, tumor growth, and lung metastasis with favorable mouse safety markers.
-
InstaBlue Protein Stain Solution Guide
2026-09-09
InstaBlue Protein Stain Solution provides rapid, fixation-free visualization of protein bands in polyacrylamide gels using a ready-to-use Coomassie Brilliant Blue formulation. It is suited to routine protein electrophoresis analysis and workflows that may lead to mass spectrometry, but detection limits, densitometric linearity, and downstream recovery should be validated for each gel system and sample type.
-
AM 281: A CB1 Receptor Antagonist Workflow
2026-09-09
AM 281 enables selective interrogation of CB1 signaling in traumatic brain injury, astrocyte–neuron assays, and memory impairment research. This workflow connects receptor pharmacology with GLT-1, CREB, excitotoxicity, and behavioral endpoints while emphasizing formulation controls and time-resolved sampling.
-
Rapid Recombinant Annexin V Purification: Study Analysis
2026-09-08
The 1993 study introduced a short, selective purification strategy for recombinant annexin V by combining mild osmotic cell opening, calcium-dependent liposome binding, and final ion-exchange chromatography. Its main contribution was not a new annexin mechanism, but a practical way to obtain sufficiently pure protein for crystallography, electron microscopy, spectroscopy, and electrophysiological measurements.
-
KU-60019: ATM Kinase Inhibitor Workflows
2026-09-08
KU-60019 combines high ATM selectivity with practical use in glioma radiosensitization, DNA repair studies, and migration assays. This guide translates its mechanism into reproducible workflows, assay controls, and troubleshooting strategies while connecting the product to emerging research on lncRNA-mediated ATM regulation.
-
DiI (DiIC18(3)) Plasma Membrane Probe
2026-09-07
DiI (DiIC18(3)) is a water-insoluble, lipophilic fluorescent dye for orange-red plasma membrane labeling in live or fixed cells and tissues. It is useful for neuronal tracing, migration, adhesion, fusion, developmental tracking, and lipoprotein workflows, but it is not an aqueous-only stain or a selective intracellular organelle marker.
-
Epinephrine Bitartrate: Adrenergic Research Workflows
2026-09-05
Build reproducible dose–response, vascular, airway, and neurobiology assays with Epinephrine Bitartrate, a broad-spectrum adrenergic receptor agonist. This guide emphasizes time-resolved measurements, practical preparation, receptor-mechanism controls, and troubleshooting rather than treating a single endpoint as proof of pathway selectivity.
-
Gastroretentive Alfuzosin Sponges: MRI Study
2026-09-05
The reference study developed low-density Alfuzosin HCl sponges from chitosan or HPMC and combined in vitro characterization with MRI-based monitoring in healthy volunteers. Its most important contribution was showing that the optimized chitosan formulation, F8, remained in the stomach for at least 5 hours, supporting gastroretention as a strategy for sustained delivery near the proximal small intestine.
-
ATRX Loss Sensitizes Glioma to RTK and PDGFR Inhibitors
2026-09-04
The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that pairing these inhibitors with temozolomide may produce stronger toxicity in ATRX-mutant tumors, supporting genotype-aware interpretation of therapeutic studies.
-
Ro 3306: CDK1 Inhibitor Workflow Guide
2026-09-04
Ro 3306 enables controlled cell cycle G2/M phase arrest, cancer cell synchronization, and mechanistic analysis of CDK1-dependent mitotic entry. This guide pairs the inhibitor with phase-resolved mTORC1, DNA repair, and recovery assays to distinguish cell-cycle blockade from metabolic or cytotoxic effects.
-
Fad2, Acsl4, and Rice Blast Pathogenicity
2026-09-03
A 2024 Mycology study links Fad2- and Acsl4-dependent phospholipid remodeling to ferroptotic conidial death, appressorium development, and Magnaporthe oryzae pathogenicity. Genetic mutants, targeted lipidomics, oxidative perturbation, and redox-interaction analysis together identify PUFA-containing phospholipids as a mechanistic connection between fungal lipid metabolism and rice blast infection.
-
Cytarabine (AraC) Apoptosis Workflows
2026-09-02
Build reproducible Cytarabine workflows for leukemia proliferation, apoptosis, DNA synthesis, and resistance studies. This guide also shows how the vIRD–RIPK3 findings from a viral immunology study can sharpen assay controls without confusing AraC-induced apoptosis with necroptosis.
-
Cycloheximide in Degradation Mechanism Assays
2026-09-02
Learn how Cycloheximide functions as a protein biosynthesis inhibitor for separating protein synthesis from degradation, interpreting apoptosis assays, and designing stronger mechanistic studies based on PAK1 research.
-
URB597 Workflows for FAAH and Pain Research
2026-09-02
URB597, also known as KDS-4103, provides selective FAAH inhibition for separating endocannabinoid target engagement from broader cannabinoid pharmacology. This practical guide connects assay design, in vivo pain models, LC-MS readouts, and troubleshooting to emerging findings in inflammatory pain research.
-
Cholecystokinin Octapeptide Ammonium: Assay Logic
2026-09-01
Cholecystokinin octapeptide ammonium (CCK-8 ammonium) is best used through receptor-resolved experimental design rather than broad pathway screening. This guide connects sulfation, CCK1R–CCK2R signaling, endogenous opioid biology, and formulation decisions to practical assay interpretation.